Related Experiment Video
Updated: Oct 16, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis
1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, 9700 West Taron Drive, Elk Grove, CA 95757, USA.
Abstract:
Cardiac fibrosis is one of the main characteristics of diabetic cardiomyopathy and manifests excessive accumulation of extracellular matrix proteins in the heart. Several signaling pathways have been proposed for pathogenesis of cardiac fibrosis in the diabetic heart. TGF-β/Smad2/3-dependent or independent pathway is the major signaling molecule core in the pathogenesis of cardiac fibrosis. MicroRNAs (miRNAs, miR) are ~22-nuceotide regulatory RNAs that are involved in gene silencing through the degradation of post-transcriptional mRNA or suppression of the expressed proteins. Hyperglycemia in the diabetic heart regulates expression of some miRNAs. Target molecules of miRNAs can be identified through biocomputational database initial screening and dual luciferase assay validation. miR-21, miR-150-5p, miR-155, miR-216a-3p, miR-221-3p, miR-223, and miR-451 were up-regulated in the diabetic heart and promoted cardiac fibrosis through targeting signaling pathways in cardiac fibroblasts, endothelial cells, and cardiac myocytes. miR-15a/-15b, miR-18a-5p, miR-20a-5p, miR-26b-5p, miR-29, miR-133a, miR-141, miR-146, miR-200b, miR-203, miR-222, and miR-551b-5p were down-regulated in the diabetic heart and exhibited anti-fibrosis when they were overexpressed. miRNAs are stable molecules and may reflect the pathological changes of organs. Some miRNAs have been detected in the plasma or serum in patients with diabetes mellitus or heart failure. Exploration of targets and biomarkers of miRNA may provide additional information on pathogenesis and diagnosis of cardiac fibrosis and novel targets to tackle diabetic cardiomyopathy.
Insights
Diabetic cardiomyopathy involves cardiac fibrosis, with microRNAs (miRNAs) playing key roles. Specific miRNAs promote fibrosis, while others inhibit it, offering potential diagnostic and therapeutic targets for diabetic heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Endocrinology
Background:
- Diabetic cardiomyopathy is characterized by cardiac fibrosis, an excessive accumulation of extracellular matrix proteins.
- The TGF-β/Smad2/3 pathway is a central signaling mechanism in the pathogenesis of cardiac fibrosis.
- MicroRNAs (miRNAs) are regulatory RNAs that modulate gene expression and are implicated in diabetic heart disease.
Purpose of the Study:
- To investigate the role of specific microRNAs (miRNAs) in the development of cardiac fibrosis in diabetic cardiomyopathy.
- To identify miRNAs that are dysregulated in the diabetic heart and their impact on cardiac fibroblast, endothelial cell, and cardiomyocyte function.
- To explore the potential of miRNAs as biomarkers and therapeutic targets for diabetic cardiomyopathy.
Main Methods:
- Bioinformatic screening and dual luciferase assays were used to identify miRNA targets.
- Expression levels of various miRNAs were analyzed in the context of diabetic heart conditions.
- Functional effects of miRNA overexpression on cardiac cells were assessed.
Main Results:
- Several miRNAs (e.g., miR-21, miR-155) were upregulated in the diabetic heart, promoting cardiac fibrosis by targeting key signaling pathways.
- Other miRNAs (e.g., miR-29, miR-133a) were downregulated and demonstrated anti-fibrotic effects upon overexpression.
- miRNAs were found to be stable and detectable in circulation, potentially reflecting cardiac pathological changes.
Conclusions:
- MicroRNAs are critical regulators of cardiac fibrosis in diabetic cardiomyopathy.
- Dysregulated miRNAs, both pro- and anti-fibrotic, represent promising biomarkers for diagnosis and novel therapeutic targets for diabetic heart disease.
- Further research into miRNA mechanisms and circulating biomarkers could advance the understanding and treatment of diabetic cardiomyopathy.
